Skip to main content
Q-Linea logo

Q-Linea — Investor Relations & Filings

Ticker · QLINEA ISIN · SE0011527845 LEI · 549300BXVB4XRM8WSC73 ST Manufacturing
Open in API
Filings indexed 322 across all filing types
Latest filing 2021-02-18 Interim / Quarterly Rep…
Country SE Sweden
Listing ST QLINEA

About Q-Linea

https://www.qlinea.com/

Q-Linea is an infection diagnostics company that develops and manufactures solutions for infectious diseases, with a primary focus on sepsis. The company's core product is the ASTar instrument, a fully automated, benchtop system that provides rapid phenotypic antimicrobial susceptibility testing (AST) directly from positive blood cultures. The ASTar system is designed to significantly reduce the time to result compared to traditional diagnostic methods, which can take up to 48 hours. By delivering faster results, the technology enables clinicians to make earlier, more informed decisions on appropriate antibiotic treatments for critically ill patients. This capability aims to improve patient outcomes, support antibiotic stewardship, and help combat the development of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Year-end report' for the period 1 January – 31 December 2020. It contains comprehensive financial statements, including income statements, cash flow analysis, and balance sheet data, as well as detailed management commentary on operational performance and significant events. Since it covers a period shorter than a full fiscal year (in the context of a quarterly/interim update) and provides substantive financial data, it is classified as an Interim/Quarterly Report. FY 2020
2021-02-18 English
Q-linea initiates pivotal clinical study for ASTar
Regulatory Filings Classification · 95% confidence The document is a short announcement (2729 characters) stating that Q-linea has started a pivotal clinical study for its product ASTar. It includes quotes from the CEO, details about the study, and contact information. Crucially, it ends with a section titled 'Attachments' linking to a PDF of the announcement itself, and a statement that the information is made public pursuant to the EU Market Abuse Regulation. This structure—a brief press release announcing a corporate event or development, often linking to the full document—fits the description of a general regulatory announcement or a report publication announcement. Since it is announcing a development (clinical study start) rather than releasing a formal financial report (like 10-K, IR, ER), and given the context of regulatory disclosure (MAR), it is best classified as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if the attached PDF is considered the primary report. Given the content is an update on clinical progress rather than the publication of a formal financial report, RNS (Regulatory Filings) is the most appropriate general category for this type of market-sensitive, non-standard report announcement.
2020-12-10 English
Q-linea startar registreringsgrundande klinisk studie för ASTar
Regulatory Filings Classification · 95% confidence The document is a press release from Q-linea AB announcing the start of a registration-enabling clinical study for their product ASTar in Europe. It discusses the study scope, risk assessment, and its role in the CE-IVD approval process. This type of announcement, detailing progress in product development or regulatory pathways, does not fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, CAP, DIRS). Since it is a general corporate update regarding product development and regulatory steps, and given the available options, it is best classified as a general Regulatory Filing (RNS) as it is a formal announcement to the market, or potentially a Legal Proceedings Report (LTR) if the study was mandated by a regulator, but RNS is the more appropriate general category for non-standard, material corporate news, especially when it references EU market abuse regulation disclosure requirements. Given the context of a clinical study start leading to market approval, RNS (Regulatory Filings/General Announcement) is the most suitable fallback.
2020-12-10 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Q-linea for the period of July 1 to September 30, 2020. It contains detailed financial statements (income statement, cash flow, balance sheet), management commentary on business trends, operational updates, and financial analysis. It is clearly a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-05 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Q-linea, covering the period from 1 July to 30 September 2020. It includes detailed financial statements (income, expenses, earnings, cash flow, and balance sheet data), management commentary on business performance, significant events, and operational updates. It is clearly a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-05 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Q-linea AB covering the period from January 1 to June 30, 2018. It contains comprehensive financial statements, including income statements, cash flow analysis, and management commentary on business performance, acquisitions, and financial position. It is not an announcement of a report, but the report itself, containing substantive financial data. H1 2018
2020-08-12 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.